ACH growth study

All right, here is the official link so the growth study which will precede the Biomarin BMN-111 phase 2 clinical trial has started recruiting. I suppose everyone has speculated that other skeletal dysplasias which are caused because of changes of FGFR3 behavior might benefit from the treatment as well... (look at the patent description here), it is very obvious that these will not be included in the initial trials, as HCH is listed as an exclusion criteria.
Not a reason not to follow the future developments though...